# Lysergic acid diethylamide
*Source: https://go.drugbank.com/drugs/DB04829*

## Overview

### Description

This compound belongs to the class of organic compounds known as lysergic acids and derivatives. These are alkaloids with a structure based on the lysergic acid skeleton.

### Background

Debate continues over the nature and causes of chronic flashbacks. Explanations in terms of LSD physically remaining in the body for months or years after consumption have been discounted by experimental evidence. Some say HPPD is a manifestation of post-traumatic stress disorder, not related to the direct action of LSD on brain chemistry, and varies according to the susceptibility of the individual to the disorder. Many emotionally intense experiences can lead to flashbacks when a person is reminded acutely of the original experience. However, not all published case reports of chronic flashbacks appear to describe an anxious hyper-vigilant state reminiscent of post-traumatic stress disorder.

### Mechanism of Action

5-hydroxytryptamine receptor 1A
Inhibitor

### Absorption

Rapidly absorbed.

### Metabolism

Hepatic.

### Half-life

3 hours

### Toxicity

Estimates for the lethal dosage (LD50) of LSD range from 200 µg/kg to more than 1 mg/kg of human body mass, though most sources report that there are no known human cases of such an overdose.

### Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

1,2-Benzodiazepine
The risk or severity of CNS depression can be increased when Lysergic acid diethylamide is combined with 1,2-Benzodiazepine.
Abametapir
The serum concentration of Lysergic acid diethylamide can be increased when it is combined with Abametapir.
Abatacept
The metabolism of Lysergic acid diethylamide can be increased when combined with Abatacept.
Abiraterone
The metabolism of Lysergic acid diethylamide can be decreased when combined with Abiraterone.
Acebutolol
Acebutolol may increase the vasoconstricting activities of Lysergic acid diethylamide.

## Chemical Information

**DrugBank ID:** DB04829

**Synonyms:** (+)-LSD
D-lysergic acid diethylamide
Diethylamid kyseliny lysergove
LSD
LSD 25
Lysergic acid diethylamide
Lysergide
Lysergidum
Lysergsäurediäthylamid
Lysergsäurediethylamid
N,N-diethyl-(+)-lysergamide
N,N-diethyl-D-lysergamide
N,N-diethyllysergamide

**Chemical Formula:** C
20
H
25
N
3
O

**SMILES:** [H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N(CC)CC

**Weight:** Average: 323.432
Monoisotopic: 323.199762437

**IUPAC Name:** (4R,7R)-N,N-diethyl-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),2,9,12,14-pentaene-4-carboxamide

## Additional Information

### Modality

Small Molecule

### Patents

0

### Indicated Conditions

0

### Phase 0

10

### Phase 1

20

### Phase 2

10

### Phase 3

0

### Phase 4

0

### Generic Name

Lysergic acid diethylamide

### DrugBank Accession Number

DB04829

### Groups

Illicit, Investigational

### Structure

3D
Download
MOL
SDF
3D-SDF
PDB
SMILES
InChI
Similar Structures
Structure for Lysergic acid diethylamide (DB04829)
×
Close

### Associated Conditions

Indication Type
Indication
Combined Product Details
Approval Level
Age Group
Patient Characteristics
Dose Form
Create Account

### Mechanism of action

Target
Actions
Organism
A
5-hydroxytryptamine receptor 1A
inhibitor
Humans
U
5-hydroxytryptamine receptor 2A
inhibitor
Humans
U
5-hydroxytryptamine receptor 2B
agonist
Humans
U
5-hydroxytryptamine receptor 6
Not Available
Humans

### International/Other Brands

Delysid (Sandoz Laboratories)

### Drug Categories

Agents that produce hypertension
Alkaloids
Antidepressive Agents
Central Nervous System Agents
Central Nervous System Depressants
Cytochrome P-450 CYP2D6 Substrates
Cytochrome P-450 CYP3A Substrates
Cytochrome P-450 CYP3A4 Substrates
Cytochrome P-450 Substrates
Ergolines
Ergot Alkaloids and Derivatives
Hallucinogens
Heterocyclic Compounds, Fused-Ring
Lysergic Acid
Neurotransmitter Agents
Psychotropic Drugs
Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
Serotonin 5-HT2 Receptor Agonists
Serotonin Agents
Serotonin Receptor Agonists
Serotonin Receptor Antagonists

### Chemical TaxonomyProvided byClassyfire

Description
This compound belongs to the class of organic compounds known as lysergic acids and derivatives. These are alkaloids with a structure based on the lysergic acid skeleton.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Ergoline and derivatives
Sub Class
Lysergic acids and derivatives
Direct Parent
Lysergic acids and derivatives
Alternative Parents
Indoloquinolines
/
Benzoquinolines
/
Quinoline-3-carboxamides
/
Pyrroloquinolines
/
3-alkylindoles
/
Isoindoles and derivatives
/
Aralkylamines
/
Benzenoids
/
Heteroaromatic compounds
/
Pyrroles
/
Tertiary carboxylic acid amides
/
Trialkylamines
/
Amino acids and derivatives
/
Azacyclic compounds
/
Organopnictogen compounds
/
Hydrocarbon derivatives
/
Carbonyl compounds
/
Organic oxides
show 8 more
Substituents
3-alkylindole
/
Amine
/
Amino acid or derivatives
/
Aralkylamine
/
Aromatic heteropolycyclic compound
/
Azacycle
/
Benzenoid
/
Benzoquinoline
/
Carbonyl group
/
Carboxamide group
/
Carboxylic acid derivative
/
Heteroaromatic compound
/
Hydrocarbon derivative
/
Indole
/
Indole or derivatives
/
Indoloquinoline
/
Isoindole or derivatives
/
Lysergic acid or derivatives
/
Organic nitrogen compound
/
Organic oxide
/
Organic oxygen compound
/
Organoheterocyclic compound
/
Organonitrogen compound
/
Organooxygen compound
/
Organopnictogen compound
/
Pyrrole
/
Pyrroloquinoline
/
Quinoline
/
Quinoline-3-carboxamide
/
Tertiary aliphatic amine
/
Tertiary amine
/
Tertiary carboxylic acid amide
show 22 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organic heterotetracyclic compound, monocarboxylic acid amide, ergoline alkaloid (
CHEBI:6605
)
/
Indole alkaloids (
C07542
)

### Kingdom

Organic compounds

### Super Class

Alkaloids and derivatives

### Class

Ergoline and derivatives

### Sub Class

Lysergic acids and derivatives

### Direct Parent

Lysergic acids and derivatives

### Alternative Parents

Indoloquinolines
/
Benzoquinolines
/
Quinoline-3-carboxamides
/
Pyrroloquinolines
/
3-alkylindoles
/
Isoindoles and derivatives
/
Aralkylamines
/
Benzenoids
/
Heteroaromatic compounds
/
Pyrroles
/
Tertiary carboxylic acid amides
/
Trialkylamines
/
Amino acids and derivatives
/
Azacyclic compounds
/
Organopnictogen compounds
/
Hydrocarbon derivatives
/
Carbonyl compounds
/
Organic oxides
show 8 more

### Substituents

3-alkylindole
/
Amine
/
Amino acid or derivatives
/
Aralkylamine
/
Aromatic heteropolycyclic compound
/
Azacycle
/
Benzenoid
/
Benzoquinoline
/
Carbonyl group
/
Carboxamide group
/
Carboxylic acid derivative
/
Heteroaromatic compound
/
Hydrocarbon derivative
/
Indole
/
Indole or derivatives
/
Indoloquinoline
/
Isoindole or derivatives
/
Lysergic acid or derivatives
/
Organic nitrogen compound
/
Organic oxide
/
Organic oxygen compound
/
Organoheterocyclic compound
/
Organonitrogen compound
/
Organooxygen compound
/
Organopnictogen compound
/
Pyrrole
/
Pyrroloquinoline
/
Quinoline
/
Quinoline-3-carboxamide
/
Tertiary aliphatic amine
/
Tertiary amine
/
Tertiary carboxylic acid amide
show 22 more

### Molecular Framework

Aromatic heteropolycyclic compounds

### External Descriptors

organic heterotetracyclic compound, monocarboxylic acid amide, ergoline alkaloid (
CHEBI:6605
)
/
Indole alkaloids (
C07542
)

### Affected organisms

Humans and other mammals

### UNII

8NA5SWF92O

### CAS number

50-37-3

### InChI Key

VAYOSLLFUXYJDT-RDTXWAMCSA-N

### InChI

InChI=1S/C20H25N3O/c1-4-23(5-2)20(24)14-9-16-15-7-6-8-17-19(15)13(11-21-17)10-18(16)22(3)12-14/h6-9,11,14,18,21H,4-5,10,12H2,1-3H3/t14-,18-/m1/s1

### Synthesis Reference

US5657570

### General References

GREINER T, BURCH NR, EDELBERG R: Psychopathology and psychophysiology of minimal LSD-25 dosage; a preliminary dosage-response spectrum. AMA Arch Neurol Psychiatry. 1958 Feb;79(2):208-10. [
Article
]
AGHAJANIAN GK, BING OH: PERSISTENCE OF LYSERGIC ACID DIETHYLAMIDE IN THE PLASMA OF HUMAN SUBJECTS. Clin Pharmacol Ther. 1964 Sep-Oct;5:611-4. [
Article
]
Papac DI, Foltz RL: Measurement of lysergic acid diethylamide (LSD) in human plasma by gas chromatography/negative ion chemical ionization mass spectrometry. J Anal Toxicol. 1990 May-Jun;14(3):189-90. [
Article
]
Nichols DE: Hallucinogens. Pharmacol Ther. 2004 Feb;101(2):131-81. [
Article
]
Jacobs BL, Heym J, Rasmussen K: Raphe neurons: firing rate correlates with size of drug response. Eur J Pharmacol. 1983 Jun 3;90(2-3):275-8. [
Article
]

### External Links

KEGG Compound
C07542
PubChem Compound
5761
PubChem Substance
46506397
ChemSpider
5558
BindingDB
21342
ChEBI
6605
ChEMBL
CHEMBL263881
ZINC
ZINC000096903803
Guide to Pharmacology
GtP Drug Page
PDBe Ligand
7LD
Wikipedia
Lysergic_acid_diethylamide

### KEGG Compound

C07542

### PubChem Compound

5761

### PubChem Substance

46506397

### ChemSpider

5558

### BindingDB

21342

### ChEBI

6605

### ChEMBL

CHEMBL263881

### ZINC

ZINC000096903803

### Guide to Pharmacology

GtP Drug Page

### PDBe Ligand

7LD

### Wikipedia

Lysergic_acid_diethylamide

### PDB Entries

5tvn
/
6wgt
/
7srq
/
7srr
/
7srs
/
7wc6
/
8fyt
/
8jxr
/
8zsp

### State

Solid

### Experimental Properties

Property
Value
Source
melting point (°C)
82.5 °C
PhysProp
logP
2.95
HANSCH,C ET AL. (1995)
pKa
7.8
SANGSTER (1994)

### Predicted Properties

Property
Value
Source
Water Solubility
0.27 mg/mL
ALOGPS
logP
3.3
ALOGPS
logP
2.28
Chemaxon
logS
-3.1
ALOGPS
pKa (Strongest Acidic)
17.02
Chemaxon
pKa (Strongest Basic)
7.98
Chemaxon
Physiological Charge
1
Chemaxon
Hydrogen Acceptor Count
2
Chemaxon
Hydrogen Donor Count
1
Chemaxon
Polar Surface Area
39.34 Å
2
Chemaxon
Rotatable Bond Count
3
Chemaxon
Refractivity
98.73 m
3
·mol
-1
Chemaxon
Polarizability
37.54 Å
3
Chemaxon
Number of Rings
4
Chemaxon
Bioavailability
1
Chemaxon
Rule of Five
Yes
Chemaxon
Ghose Filter
Yes
Chemaxon
Veber's Rule
Yes
Chemaxon
MDDR-like Rule
No
Chemaxon

### Predicted ADMET Features

Property
Value
Probability
Human Intestinal Absorption
+
1.0
Blood Brain Barrier
+
0.9775
Caco-2 permeable
-
0.5938
P-glycoprotein substrate
Substrate
0.7616
P-glycoprotein inhibitor I
Inhibitor
0.8066
P-glycoprotein inhibitor II
Inhibitor
0.7347
Renal organic cation transporter
Inhibitor
0.5699
CYP450 2C9 substrate
Non-substrate
0.8544
CYP450 2D6 substrate
Non-substrate
0.6804
CYP450 3A4 substrate
Substrate
0.7593
CYP450 1A2 substrate
Non-inhibitor
0.5399
CYP450 2C9 inhibitor
Non-inhibitor
0.8509
CYP450 2D6 inhibitor
Inhibitor
0.6612
CYP450 2C19 inhibitor
Non-inhibitor
0.8438
CYP450 3A4 inhibitor
Non-inhibitor
0.6198
CYP450 inhibitory promiscuity
Low CYP Inhibitory Promiscuity
0.629
Ames test
AMES toxic
0.634
Carcinogenicity
Non-carcinogens
0.9157
Biodegradation
Not ready biodegradable
0.9564
Rat acute toxicity
3.1459 LD50, mol/kg
Not applicable
hERG inhibition (predictor I)
Weak inhibitor
0.8864
hERG inhibition (predictor II)
Inhibitor
0.5
ADMET data is predicted using
admetSAR
, a free tool for evaluating chemical ADMET properties. (
23092397
)

### Mass Spec (NIST)

Download
(10.1 KB)

### Spectra

Spectrum
Spectrum Type
Splash Key
GC-MS Spectrum - EI-B
GC-MS
splash10-00di-2974000000-f1e2685ff289086cda8e
Mass Spectrum (Electron Ionization)
MS
splash10-00di-1894000000-61a7a87f966b104602ec
Predicted MS/MS Spectrum - 10V, Positive (Annotated)
Predicted LC-MS/MS
splash10-00di-0029000000-76da022d959c61a78f5b
Predicted MS/MS Spectrum - 10V, Negative (Annotated)
Predicted LC-MS/MS
splash10-00di-0009000000-4c48c43c81071adec5cd
Predicted MS/MS Spectrum - 20V, Positive (Annotated)
Predicted LC-MS/MS
splash10-0fk9-0094000000-80d967ead8b660e91345
Predicted MS/MS Spectrum - 20V, Negative (Annotated)
Predicted LC-MS/MS
splash10-00di-6059000000-6daf4093b958b1579630
Predicted MS/MS Spectrum - 40V, Positive (Annotated)
Predicted LC-MS/MS
splash10-00ur-1590000000-b78d73ba46f8d510788d
Predicted MS/MS Spectrum - 40V, Negative (Annotated)
Predicted LC-MS/MS
splash10-05fr-2190000000-ad326adff9154565c790
Predicted 1H NMR Spectrum
1D NMR
Not Applicable
Predicted 13C NMR Spectrum
1D NMR
Not Applicable

### Chromatographic Properties

Collision Cross Sections (CCS)
Adduct
CCS Value (Å
2
)
Source type
Source
[M-H]-
188.9268088
predicted
DarkChem Lite v0.1.0
[M-H]-
179.54936
predicted
DeepCCS 1.0 (2019)
[M+H]+
188.1059088
predicted
DarkChem Lite v0.1.0
[M+H]+
181.90736
predicted
DeepCCS 1.0 (2019)
[M+Na]+
189.8655088
predicted
DarkChem Lite v0.1.0
[M+Na]+
188.41304
predicted
DeepCCS 1.0 (2019)

### Kind

Protein

### Organism

Humans

### Pharmacological action

No

### Actions

Substrate

### General Function

A cytochrome P450 monooxygenase involved in the metabolism of fatty acids, steroids and retinoids (PubMed:18698000, PubMed:19965576, PubMed:20972997, PubMed:21289075, PubMed:21576599). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:18698000, PubMed:19965576, PubMed:20972997, PubMed:21289075, PubMed:21576599). Catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA) (PubMed:19965576, PubMed:20972997). Metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 20-hydroxyeicosatetraenoic acid ethanolamide (20-HETE-EA) and 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling (PubMed:18698000, PubMed:21289075). Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis (PubMed:21576599). Catalyzes the oxidative transformations of all-trans retinol to all-trans retinal, a precursor for the active form all-trans-retinoic acid (PubMed:10681376). Also involved in the oxidative metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants

### Specific Function

anandamide 11,12 epoxidase activity

### Gene Name

CYP2D6

### Uniprot ID

P10635

### Uniprot Name

Cytochrome P450 2D6

### Molecular Weight

55768.94 Da

